Guminski A - Search Results

1

Overall survival with [¹⁷⁷Lu]Lu-PSMA-617 versus cabazitaxel in metastatic castration-resistant prostate cancer (TheraP): secondary outcomes of a randomised, open-label, phase 2 trial.

Hofman MS, Emmett L, Sandhu S, Iravani A, Buteau JP, Joshua AM, Goh JC, Pattison DA, Tan TH, Kirkwood ID, Ng S, Francis RJ, Gedye C, Rutherford NK, Weickhardt A, Scott AM, Lee ST, Kwan EM, Azad AA, Ramdave S, Redfern AD, Macdonald W, Guminski A, Hsiao E, Chua W, Lin P, Zhang AY, Stockler MR, Williams SG, Martin AJ, Davis ID; TheraP Trial Investigators and the Australian and New Zealand Urogenital and Prostate Cancer Trials Group. Hofman MS, et al. Among authors: guminski a. Lancet Oncol. 2024 Jan;25(1):99-107. doi: 10.1016/S1470-2045(23)00529-6. Epub 2023 Nov 30. Lancet Oncol. 2024. PMID: 38043558 Clinical Trial.

2

Role of intratumoural heterogeneity in cancer drug resistance: molecular and clinical perspectives.

Saunders NA, Simpson F, Thompson EW, Hill MM, Endo-Munoz L, Leggatt G, Minchin RF, Guminski A. Saunders NA, et al. Among authors: guminski a. EMBO Mol Med. 2012 Aug;4(8):675-84. doi: 10.1002/emmm.201101131. Epub 2012 Jun 25. EMBO Mol Med. 2012. PMID: 22733553 Free PMC article. Review.

3

Focal overexpression of CEACAM6 contributes to enhanced tumourigenesis in head and neck cancer via suppression of apoptosis.

Cameron S, de Long LM, Hazar-Rethinam M, Topkas E, Endo-Munoz L, Cumming A, Gannon O, Guminski A, Saunders N. Cameron S, et al. Among authors: guminski a. Mol Cancer. 2012 Sep 28;11:74. doi: 10.1186/1476-4598-11-74. Mol Cancer. 2012. PMID: 23021083 Free PMC article.

4

Tumor-initiating activity and tumor morphology of HNSCC is modulated by interactions between clonal variants within the tumor.

Cameron SR, Dahler AL, Endo-Munoz LB, Jabbar I, Thomas GP, Leo PJ, Poth K, Rickwood D, Guminski A, Saunders NA. Cameron SR, et al. Among authors: guminski a. Lab Invest. 2010 Nov;90(11):1594-603. doi: 10.1038/labinvest.2010.131. Epub 2010 Jul 26. Lab Invest. 2010. PMID: 20661227 Free article.

5

Preclinical evaluation of dual PI3K-mTOR inhibitors and histone deacetylase inhibitors in head and neck squamous cell carcinoma.

Erlich RB, Kherrouche Z, Rickwood D, Endo-Munoz L, Cameron S, Dahler A, Hazar-Rethinam M, de Long LM, Wooley K, Guminski A, Saunders NA. Erlich RB, et al. Among authors: guminski a. Br J Cancer. 2012 Jan 3;106(1):107-15. doi: 10.1038/bjc.2011.495. Epub 2011 Nov 24. Br J Cancer. 2012. PMID: 22116303 Free PMC article.

6

Loss of osteoclasts contributes to development of osteosarcoma pulmonary metastases.

Endo-Munoz L, Cumming A, Rickwood D, Wilson D, Cueva C, Ng C, Strutton G, Cassady AI, Evdokiou A, Sommerville S, Dickinson I, Guminski A, Saunders NA. Endo-Munoz L, et al. Among authors: guminski a. Cancer Res. 2010 Sep 15;70(18):7063-72. doi: 10.1158/0008-5472.CAN-09-4291. Epub 2010 Sep 7. Cancer Res. 2010. PMID: 20823153

7

Cisplatin treatment induces a transient increase in tumorigenic potential associated with high interleukin-6 expression in head and neck squamous cell carcinoma.

Poth KJ, Guminski AD, Thomas GP, Leo PJ, Jabbar IA, Saunders NA. Poth KJ, et al. Among authors: guminski ad. Mol Cancer Ther. 2010 Aug;9(8):2430-9. doi: 10.1158/1535-7163.MCT-10-0258. Epub 2010 Aug 3. Mol Cancer Ther. 2010. PMID: 20682658

8

The deubiquitinase USP9X suppresses pancreatic ductal adenocarcinoma.

Pérez-Mancera PA, Rust AG, van der Weyden L, Kristiansen G, Li A, Sarver AL, Silverstein KA, Grützmann R, Aust D, Rümmele P, Knösel T, Herd C, Stemple DL, Kettleborough R, Brosnan JA, Li A, Morgan R, Knight S, Yu J, Stegeman S, Collier LS, ten Hoeve JJ, de Ridder J, Klein AP, Goggins M, Hruban RH, Chang DK, Biankin AV, Grimmond SM; Australian Pancreatic Cancer Genome Initiative; Wessels LF, Wood SA, Iacobuzio-Donahue CA, Pilarsky C, Largaespada DA, Adams DJ, Tuveson DA. Pérez-Mancera PA, et al. Nature. 2012 Apr 29;486(7402):266-70. doi: 10.1038/nature11114. Nature. 2012. PMID: 22699621 Free PMC article.

9

Indole-3-carbinol - induced growth inhibition can be converted to a cytotoxic response in the presence of TPA+Ca(2+) in squamous cell carcinoma cell lines.

Dahler AL, Rickwood D, Guminski A, Teakle N, Saunders NA. Dahler AL, et al. Among authors: guminski a. FEBS Lett. 2007 Aug 7;581(20):3839-47. doi: 10.1016/j.febslet.2007.07.009. Epub 2007 Jul 16. FEBS Lett. 2007. PMID: 17659285 Free article.

10

Carboplatin and paclitaxel interact antagonistically in a megakaryoblast cell line--a potential mechanism for paclitaxel-mediated sparing of carboplatin-induced thrombocytopenia.

Guminski AD, Harnett PR, deFazio A. Guminski AD, et al. Cancer Chemother Pharmacol. 2001 Sep;48(3):229-34. doi: 10.1007/s002800100279. Cancer Chemother Pharmacol. 2001. PMID: 11592345

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

121 results

Search Page